Jasper Therapeutics confirms CVR terms: $30M milestone if FDA issues Priority Review Voucher for briquilimab by Dec 2028

Jasper Therapeutics, Inc.

Each share of common stock as of July 16, 2026 (closing date) receives one CVR.
CVRs entitle holders to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab on or before Dec 31, 2028.
If milestone achieved and change of control occurs, payment on earlier of change of control consummation or 90 days after monetization event.
CVRs are non-transferable, not certificated, not registered with SEC, not listed on any exchange.
CVRs continue if milestone achieved but monetization not yet occurred; payment due 90 days after monetization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.